CompletedEUCTR 2020-005457-25

A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression

This historical record does not confirm current site availability.

Historical research recordMultiple countries

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Germany · Italy and 1 more location
Study phase: Phase 2

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 93
Sponsor: Perception Neuroscience, Inc
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: Germany, Italy, Poland
Age range: Not clearly listed
Official registry ID: EUCTR 2020-005457-25
Official title: Show the full official title
A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression

Looking for a study you can join?

Explore recruiting studies

Get this study by email

Recruitment & locations

Completed

Germany · Italy · Poland

Registry details

Historical country statuses

Germany — Completed
Italy — Completed
Poland — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Perception Neuroscience, Inc.

Explore other studies

Want to find a study that may fit you better?

Explore HopeStage studies by mental health topic and refine the results to suit your situation.

Find a study that may fit me